Abstract: The present disclosure relates to an antibody binding specifically to tryptophanyl-tRNA synthetase (WARS) or a fragment thereof. The antibody or the fragment thereof of the present disclosure has an excellent ability to bind specifically to WARS with no cross-reactivity with other ARSs and has an excellent ability to detect WARS and inhibit the activity thereof. Therefore, it can be effectively used for diagnosing and/or treating an infectious disease.
Abstract: The present disclosure relates to a method for determining the mortality risk of an infectious inflammatory disease on the basis of the concentrations of tryptophanyl-tRNA synthetase (WARS) and cytokines. The method for determining the mortality risk of the present disclosure can effectively identify patients who are at high risk of mortality due to an infectious inflammatory disease within a short period of time and, as such, can be very helpful for performing timely therapy.
Abstract: The present invention relates to a composition for treatment or prevention of infectious inflammatory diseases comprising tryptophanyl-tRNA synthetase as an active ingredient, and a composition for immune enhancement. More specifically, the present invention relates to a pharmaceutical composition for treatment or prevention of infectious inflammatory diseasess comprising tryptophanyl-tRNA synthetase as an active ingredient, a food composition for preventing or improving, a veterinary composition for preventing or treating, and a composition for immune enhancement comprising a tryptophanyl-tRNA synthetase as an active ingredient, respectively. The composition of the present invention can be effectively used for preventing or treating diseases of humans and animals caused by infection from bacteria, viruses or fungi and the like by inhibiting infections such as bacterial, viral, and fungal infections at an early stage particularly through activating innate immune response.